Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Operating Leases: 2019-2024

Historic Operating Leases for Wave Life Sciences (WVE) over the last 6 years, with Dec 2024 value amounting to $17.8 million.

  • Wave Life Sciences' Operating Leases fell 42.45% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 42.45%. This contributed to the annual value of $17.8 million for FY2024, which is 30.07% down from last year.
  • Per Wave Life Sciences' latest filing, its Operating Leases stood at $17.8 million for FY2024, which was down 30.07% from $25.4 million recorded in FY2023.
  • Over the past 5 years, Wave Life Sciences' Operating Leases peaked at $32.1 million during FY2022, and registered a low of $17.8 million during FY2024.
  • Over the past 3 years, Wave Life Sciences' median Operating Leases value was $25.4 million (recorded in 2023), while the average stood at $25.1 million.
  • Per our database at Business Quant, Wave Life Sciences' Operating Leases grew by 28.70% in 2022 and then tumbled by 30.07% in 2024.
  • Yearly analysis of 5 years shows Wave Life Sciences' Operating Leases stood at $25.6 million in 2020, then fell by 2.49% to $25.0 million in 2021, then grew by 28.70% to $32.1 million in 2022, then decreased by 20.90% to $25.4 million in 2023, then plummeted by 30.07% to $17.8 million in 2024.